Head-To-Head Comparison: MannKind (MNKD) versus The Competition

MannKind (NASDAQ:MNKD) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare MannKind to similar businesses based on the strength of its valuation, analyst recommendations, risk, dividends, earnings, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for MannKind and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1	2	7	0	2.60
MannKind Competitors	9903	15310	45655	1602	2.54

MannKind currently has a consensus target price of $8.50, suggesting a potential upside of 105.81%. As a group, “Biotechnology” companies have a potential upside of 126.26%. Given MannKind’s peers higher possible upside, analysts plainly believe MannKind has less favorable growth aspects than its peers.

Volatility & Risk

MannKind has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, MannKind’s peers have a beta of -1.88, meaning that their average stock price is 288% less volatile than the S&P 500.

Profitability

This table compares MannKind and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MannKind	-18.10%	N/A	-10.01%
MannKind Competitors	-12,319.70%	-407.93%	-30.95%

Valuation & Earnings

This table compares MannKind and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MannKind	$348.97 million	$5.86 million	-17.96
MannKind Competitors	$718.54 million	$11.20 million	-18.80

MannKind’s peers have higher revenue and earnings than MannKind. MannKind is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

49.5% of MannKind shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

MannKind beats its peers on 8 of the 13 factors compared.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).